Longwood Healthcare Leaders
Stanford/San Francisco CEO
January 6 - 7, 2024
Longwood Healthcare Leaders Stanford/San Francisco CEO brings together leading biopharma CEOs, heads of R&D, top academic researchers, and life science investors the weekend prior to the JP Morgan Healthcare Conference for off-the-record discussion, co-hosted by Stanford Med Dean Lloyd Minor and former Stanford President Marc Tessier-Lavigne, held at the Four Seasons San Francisco.
​
Join us for an intimate event with leaders in the industry.
Featured Speakers
Agenda
Saturday, January 6, 2024
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
8:00 am
BIG BIOPHARMA PIPELINE SOURCING
Shiva Malek, Global Head, Oncology, Novartis
Frank Nestle, Global Head, Research & CSO, Sanofi
8:30 am
CROSS-BORDER COLLABORATION
Ed Hu, Vice Chair & Global CIO, WuXi
9:00 am
FIRESIDE CHAT
Lloyd Minor, Dean, Stanford School of Medicine
Marc Tessier-Lavigne, former President, Stanford University
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:20 am
ENSURING HEALTH EQUITY AND ACCESS
Steve Hahn, CEO, Harbinger Health; former Commissioner, FDA
Sabrina Johnson, CEO, Daré Bioscience
9:50 am
NETWORKING BREAK
10:20 am
R&D COLLABORATION
Johan Luthman, EVP, R&D, Lundbeck
Zhen Su, CEO, Marengo Therapeutics
10:50 am
ACCELERATING DRUG DEVELOPMENT
Larry Hamann, CEO, Interdict Bio
Carl Hansen, CEO, Abcellera
11:20 am
RECRUITING AND RETAINING TALENT
11:50 am
FIRESIDE CHAT: FROM PHARMA TO BIOTECH CEO
Hal Barron, CEO, Altos Labs
Mathai Mammen, CEO, FogPharma
12:10 pm
NETWORKING LUNCHEON
1:00 pm
RARE DISEASE INNOVATION
Shalini Sharp, former CFO, Ultragenyx
1:30 pm
GETTING TO REGULATORY APPROVAL
Moderator: Ken Drazan, CEO, ArsenalBio
2:00 pm
DEAL-MAKING LANDSCAPE
Matthias Muellenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
Ioannis Sapountzis, SVP, Corporate BD&L, Boehringer Ingelheim
2:30 pm
INNOVATIVE COMMERCIAL MODELS
Teresa Bitetti, President, Global Oncology, Takeda
3:00 pm
NETWORKING BREAK
3:30 pm
REGULATORY KEYNOTE
Peter Marks, Director, CBER, FDA
4:00 pm
THE FUTURE OF GENETIC THERAPIES
4:30 pm
STRENGTH IN THE SYNDICATE
Vik Bajaj, Managing Director, Foresite Capital
5:00 – 7:00 pm
COCKTAIL RECEPTION
Sunday, January 7, 2024
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
8:00 am
R&D TRANSFORMATION
Anirvan Ghosh, CEO, Unity Biotechnology
Liz Thompson, EVP, R&D, Horizon Therapeutics
8:30 am
INNOVATION IN CLINICAL TRIAL DESIGN
John Glasspool, CEO, Anthos Therapeutics
Paulo Fontoura, SVP, Neuroscience, Immunology, Ophthalmology, Infectious & Rare Diseases Clinical Development, Roche
9:00 am
PLATFORM TO PRODUCT PLAY
9:30 am
FIRESIDE CHAT
Rochelle Walensky, Director, CDC (2021-2023)
9:50 am
NETWORKING BREAK
10:20 am
BIG BIOPHARMA R&D
10:50 am
MAINTAINING FOCUS ON THE PATIENT
David Loew, CEO, Ipsen
11:20 am
EVOLVING PARTNERING STRATEGY
Anat Naschitz, CEO, 9xc
Uli Stilz, VP, Bio Innovation Hub, Novo Nordisk
Matt Tremblay, CEO, Blackbird Labs
11:50 am
MANAGING THE RUNWAY
12:20 pm
NETWORKING LUNCHEON
1:00 pm
POLICY IMPACT ON INNOVATON
1:30 pm
ADVANCING RESEARCH INTO THE CLINIC
Stewart Campbell, CEO, Axial Therapeutics
Robert LaCaze, CEO, Mnemo Therapeutics
Sunil Verma, SVP, Global Medical Affairs, Oncology, AstraZeneca
2:00 pm
FIRESIDE CHAT: PHARMA R&D TRENDS
2:20 pm
NETWORKING BREAK
2:40 pm
THE NEXT WAVE OF TARGETED THERAPIES
Janice Chen, CTO, Mammoth Biosciences
Phil Vickers, CEO, Solu Therapeutics
2:50 pm
EXTERNAL INNOVATION
Jeb Keiper, CEO, Nimbus Therapeutics
3:20 pm
INVESTMENT OUTLOOK
